Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma
Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma
复制标题
抗 TSLP 抗体 Tezepelumab 治疗哮喘的临床研究最新摘要
DOI：
10.1016/j.alit.2022.11.006
复制
发表时间：
2023
影响因子：
6.8
通讯作者：
Fukunaga Koichi
中科院分区：
文献类型：
--
作者：
Kurihara Momoko;Kabata Hiroki;Irie Misato;Fukunaga Koichi
胸腺基质淋巴细胞生成素（TSLP）是一种上皮细胞源性细胞因子，通过先天性和获得性免疫级联反应在诱导2型炎症中起重要作用。Tezepelumab是一种抑制TSLP与TSLP受体结合的人IgG 2单克隆抗体，是治疗哮喘的最新生物制品。为了评价tezepelumab在哮喘中的疗效和机制，进行了PATHWAY、NAVIGATOR、NOZOMI、UPSTREAM、CASCADE、SOURCE和DESTINATION研究。这些结果表明，tezepelumab是一种广泛靶向的生物制剂，预期对控制不佳的中重度哮喘患者有效，无论表型如何，尽管其在口服皮质类固醇依赖性哮喘中的疗效、非2型表型的生物学机制和长期安全性仍未知。在这篇综述中，我们总结了tezepelumab治疗哮喘的临床试验结果，并讨论了tezepelumab与其他生物制剂之间的差异。© 2022日本变态反应学会。由Elsevier BV发布这是CC BY-NC-ND许可证下的开放获取文章（http：//creativecommons. org/licenses/by-nc-nd/4.0/）。
Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine that plays a vital role in the induction of type 2 inflammation via both innate and acquired immune cascades. Tezepelumab, a human IgG2 monoclonal antibody that inhibits the binding of TSLP to the TSLP receptor, is the latest biologic for asthma. To evaluate the efficacy and mechanism of tezepelumab in asthma, the PATHWAY, NAVIGATOR, NOZOMI, UPSTREAM, CASCADE, SOURCE, and DESTINATION studies have been conducted. These results suggested that tezepelumab is a broad-target biologic, which is expected to be effective in patients with poorly controlled moderate to severe asthma regardless of the phenotype, although its efficacy in oral corticosteroids-dependent asthma, biological mechanism in non-type 2 phenotype, and long-term safety remain unknown. In this review, we summarize the results of clinical trials of tezepelumab in asthma and discuss the differences between tezepelumab and other biologics.© 2022 Japanese Society of Allergology. Published by Elsevier BV This is an open access article under the CC BY-NC-ND license (http://creativecommons. org/licenses/by-nc-nd/4.0/).